Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Part of paid clinical trials in La Jolla, California.

Sponsor
AstraZeneca
Study ID
NCT06465810
Status
Recruiting
Apply to this trial

Conditions

  • ATTR
  • ATTR-CM
  • ATTR-Mixed
  • ATTRv-PN
  • Transthyretin Amyloidosis
  • hATTR

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

  • Treatment of transthyretin (ATTR) amyloidosis in observational study setting — DRUG
    Data will be collected on patients with ATTR amyloidosis in a real-world setting

Study Details

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Key Dates

Start date
Jun 25, 2024
Status verified
May 2026
Primary completion
Dec 29, 2031
Completion
Dec 29, 2031

Study Design

Enrollment
1,850 participants (estimated)

Arms

  • Arm: ATTR cardiomyopathy (ATTR-CM)
    Patients with ATTR-CM at enrollment
  • Arm: Hereditary polyneuropathy (ATTRv-PN)
    Patients with ATTRv-PN at enrollment
  • Arm: ATTR-Mixed
    Patients with a mixed ATTR amyloidosis phenotype

Primary Outcome Measure

Demographic characteristics (overall and in patients initiating a treatment with eplontersen) [ Time Frame: From time of enrollment for up to 7 years ]

Central Contacts

Locations (30)

FacilityCityStateZIPSite coordinators
Research SiteLa JollaCalifornia92037-
Research SiteLos AngelesCalifornia90095-
Research SiteSan FranciscoCalifornia94025-
Research SiteSan FranciscoCalifornia94143-
Research SiteNew HavenConnecticut06510-
Research SiteWashington D.C.District of Columbia20010-
Research SiteChicagoIllinois60637-
Research SiteIndianapolisIndiana06200-
Research SiteBostonMassachusetts02111-
Research SiteBostonMassachusetts02114-
Research SiteBostonMassachusetts02115-
Research SiteRochesterMinnesota55905-
Research SiteKansas CityMissouri64111-
Research SiteSt LouisMissouri63110-
Research SiteNew BrunswickNew Jersey08901-
Research SiteManhassetNew York11030-
Research SiteNew YorkNew York10027-
Research SiteNew YorkNew York10029-
Research SiteDurhamNorth Carolina27710-
Research SitePortlandOregon97239-
Research SiteDanvillePennsylvania17822-
Research SitePhiladelphiaPennsylvania19104-
Research SitePhiladelphiaPennsylvania19107-
Research SiteGreenvilleSouth Carolina29607-
Research SiteGermantownTennessee38138-
Research SiteNashvilleTennessee37214-
Research SiteDallasTexas75246-
Research SiteRichmondVirginia23298-
Research SiteSeattleWashington98915-
Research SiteMilwaukeeWisconsin53226-

Find similar trials in La Jolla, CA

By research site
Research Site· La Jolla, CAResearch Site· Los Angeles, CAResearch Site· San Francisco, CAResearch Site· New Haven, CTResearch Site· Washington D.C., DCResearch Site· Chicago, IL

Related Studies